ProPhase Labs, Inc. Gain (Loss) on Extinguishment of Debt
ProPhase Labs, Inc. (PRPH) reported Gain (Loss) on Extinguishment of Debt of $398.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-08-19
- ProPhase Labs, Inc. gain (loss) on extinguishment of debt for the quarter ending 2026-06-30 was $398.00K.
- ProPhase Labs, Inc. gain (loss) on extinguishment of debt for the quarter ending 2026-03-31 was -$278.00K.
- ProPhase Labs, Inc. gain (loss) on extinguishment of debt for the quarter ending 2025-12-31 was $1.34M.
- ProPhase Labs, Inc. gain (loss) on extinguishment of debt for the quarter ending 2025-09-30 was $220.00K.
- ProPhase Labs, Inc. gain (loss) on extinguishment of debt for fiscal 2025 was $838.00K.
- ProPhase Labs, Inc. gain (loss) on extinguishment of debt for fiscal 2024 was -$333.00K.
- ProPhase Labs, Inc. gain (loss) on extinguishment of debt for fiscal 2023 was $0.00.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $398.00K 10-Q · filed 2026-08-19 | $120.00K 10-Q · filed 2026-08-19 | $1.46M derived: sum of 3 quarters · filed 2026-08-19 | $1.68M derived: sum of 4 quarters · filed 2026-08-19 |
| 2026-03-31 | -$278.00K 10-Q/A · filed 2026-07-09 | $1.06M derived: sum of 2 quarters · filed 2026-07-09 | $1.28M derived: sum of 3 quarters · filed 2026-07-09 | $991.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-12-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $1.56M derived: sum of 2 quarters · filed 2026-06-01 | $1.27M derived: sum of 3 quarters · filed 2026-08-19 | $838.00K 10-K · filed 2026-06-01 |
| 2025-09-30 | $220.00K 10-Q · filed 2025-11-19 | -$67.00K derived: sum of 2 quarters · filed 2026-08-19 | -$498.00K 10-Q · filed 2025-11-19 | -$831.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | -$287.00K 10-Q · filed 2026-08-19 | -$718.00K 10-Q · filed 2026-08-19 | -$1.05M derived: sum of 3 quarters · filed 2026-08-19 | -$1.05M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-03-31 | -$431.00K 10-Q/A · filed 2026-07-09 | -$764.00K derived: sum of 2 quarters · filed 2026-07-09 | -$764.00K derived: sum of 3 quarters · filed 2026-07-09 | -$764.00K derived: sum of 4 quarters · filed 2026-07-09 |
| 2024-12-31 | -$333.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | -$333.00K derived: sum of 2 quarters · filed 2026-06-01 | -$333.00K derived: sum of 3 quarters · filed 2026-06-01 | -$333.00K 10-K · filed 2026-06-01 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-19 | $0.00 derived: sum of 2 quarters · filed 2025-11-19 | $0.00 10-Q · filed 2025-11-19 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-20 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |